See more : Transgene SA (TNG.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shaanxi Meibang Pharmaceutical Group Co., Ltd., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- SAB Industries Limited (SAB.BO) Income Statement Analysis – Financial Results
- Shanghai Shimao Co., Ltd. (600823.SS) Income Statement Analysis – Financial Results
- BYTE Acquisition Corp. (BYTS) Income Statement Analysis – Financial Results
- Gayatri Projects Limited (GAYAPROJ.BO) Income Statement Analysis – Financial Results
- Lithium Plus Minerals Ltd (LPM.AX) Income Statement Analysis – Financial Results
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
About Shaanxi Meibang Pharmaceutical Group Co., Ltd.
Shaanxi Meibang Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of pesticide preparations. Its products include fungicides and insecticides. The company was founded in 1998 and is based in Weinan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 699.03M | 906.05M | 842.49M | 568.52M | 515.71M | 438.56M | 421.96M |
| Cost of Revenue | 478.04M | 518.86M | 520.06M | 361.86M | 314.17M | 274.35M | 267.49M |
| Gross Profit | 220.99M | 387.19M | 322.43M | 206.65M | 201.54M | 164.21M | 154.47M |
| Gross Profit Ratio | 31.61% | 42.73% | 38.27% | 36.35% | 39.08% | 37.44% | 36.61% |
| Research & Development | 58.53M | 80.04M | 63.81M | 51.36M | 39.52M | 26.93M | 26.35M |
| General & Administrative | 9.29M | 7.93M | 11.59M | 4.82M | 5.17M | 9.46M | 11.96M |
| Selling & Marketing | 85.42M | 122.65M | 88.27M | 45.89M | 45.75M | 35.84M | 35.24M |
| SG&A | 94.71M | 130.57M | 99.86M | 50.71M | 50.91M | 45.30M | 47.20M |
| Other Expenses | 12.04M | 26.05M | 19.74M | 13.03M | 12.08M | 554.07K | 57.75K |
| Operating Expenses | 188.73M | 236.67M | 183.41M | 115.10M | 102.51M | 83.23M | 75.70M |
| Cost & Expenses | 648.66M | 755.52M | 703.47M | 476.97M | 416.67M | 357.58M | 343.19M |
| Interest Income | 2.00M | 2.75M | 1.70M | 491.69K | 356.70K | 277.46K | 0.00 |
| Interest Expense | 506.87K | 979.49K | 3.31M | 852.76K | 2.98M | 4.37M | 0.00 |
| Depreciation & Amortization | 21.22M | 15.82M | 12.54M | 10.57M | 10.32M | 8.32M | 351.00K |
| EBITDA | 84.13M | 150.05M | 154.62M | 100.90M | 97.79M | 79.92M | 79.12M |
| EBITDA Ratio | 12.04% | 20.40% | 20.22% | 17.51% | 19.70% | 19.22% | 20.16% |
| Operating Income | 50.37M | 140.27M | 122.50M | 87.59M | 86.05M | 66.86M | 69.88M |
| Operating Income Ratio | 7.21% | 15.48% | 14.54% | 15.41% | 16.69% | 15.25% | 16.56% |
| Total Other Income/Expenses | 12.04M | 12.09M | 16.33M | 1.79M | -544.62K | -4.19M | 57.76K |
| Income Before Tax | 62.41M | 152.37M | 138.83M | 89.39M | 85.50M | 67.42M | 69.94M |
| Income Before Tax Ratio | 8.93% | 16.82% | 16.48% | 15.72% | 16.58% | 15.37% | 16.57% |
| Income Tax Expense | 4.85M | 7.28M | 13.09M | 10.65M | 9.25M | 8.08M | 8.71M |
| Net Income | 57.56M | 145.09M | 125.74M | 78.73M | 76.26M | 59.33M | 61.22M |
| Net Income Ratio | 8.23% | 16.01% | 14.93% | 13.85% | 14.79% | 13.53% | 14.51% |
| EPS | 0.43 | 1.07 | 0.93 | 0.58 | 0.56 | 0.63 | 0.68 |
| EPS Diluted | 0.43 | 1.07 | 0.93 | 0.58 | 0.56 | 0.63 | 0.68 |
| Weighted Avg Shares Out | 133.85M | 135.20M | 135.20M | 135.20M | 135.20M | 94.18M | 90.04M |
| Weighted Avg Shares Out (Dil) | 133.85M | 135.20M | 135.20M | 135.20M | 135.20M | 94.18M | 90.04M |
Source: https://incomestatements.info
Category: Stock Reports